Mast Hücresi ve Kutanöz Mastositozda D Vitamini
Özet
Mast hücreleri, deri, mukoza ve bağ dokularında yer alan, aktive olduklarında histamin ve sitokin gibi inflamatuar aracıları salgılayarak alerjik ve inflamatuar süreçleri başlatan bağışıklık sistemi bileşenleridir. Mastositoz ise bu hücrelerin klonal genişlemesi ve anormal aktivasyonuyla karakterize, özellikle çocuklarda kutanöz (deri) formda görülen heterojen bir miyeloid neoplazmdır. Hastalığın patogenezi çoğunlukla C-KIT genindeki somatik fonksiyon kazanımı mutasyonlarıyla ilişkilidir. Mast hücreleri D vitamini reseptörü (VDR) eksprese etmekte olup 1,25(OH)2D3 formundaki D vitamini, bu hücrelerin gelişimini, farklılaşmasını ve fonksiyonunu azaltarak aktivasyonlarını inhibe eder ve stabilizasyonlarına katkıda bulunur. D vitamini eksikliğinde mast hücrelerinin kendiliğinden aktive olması, bu metabolizmanın önemini göstermektedir. Klinik açıdan kutanöz mastositoz; makülopapüler, diffüz ve soliter mastositoma olarak üç alt gruba ayrılır; tanı ise Darier belirtisi ve cilt biyopsisiyle konur. Semptom yönetiminde antihistaminikler, antilökotrienler ve kortikosteroidler kullanılırken, anafilaksi riski nedeniyle epinefrin otoenjektörü bulundurulması kritiktir. Terapötik stratejiler belirlenirken D vitamini eksikliğinin dikkate alınması hastalık yönetimine katkı sağlamaktadır.
Mast cells are immune system components located in the skin, mucosa, and connective tissues that initiate allergic and inflammatory processes by releasing mediators such as histamine and cytokines upon activation. Mastocytosis is a heterogeneous myeloid neoplasm characterized by the clonal expansion and abnormal activation of these cells, predominantly manifesting in children as the cutaneous (skin) form. The pathogenesis of the disease is largely linked to somatic gain-of-function mutations in the C-KIT gene. Mast cells express the vitamin D receptor (VDR), and vitamin D in the form of 1,25(OH)2D3 inhibits mast cell activation and contributes to their stabilization by reducing their development, differentiation, and function. The automatic activation of mast cells in vitamin D-deficient environments demonstrates the significance of this metabolism. Clinically, cutaneous mastocytosis is divided into three subforms: maculopapular, diffuse, and solitary mastocytoma; diagnosis is confirmed via Darier's sign and skin biopsy. While antihistamines, antileukotrienes, and corticosteroids are used for symptom management, carrying an epinephrine auto-injector is critical due to anaphylaxis risks. Considering vitamin D deficiency when determining therapeutic strategies contributes significantly to disease management.
Referanslar
Soter NA. The skin in mastocytosis. J Invest Dermatol 1991;96. 1523-47
Wernersson S, Pejler G. Mast cell secretory granules: Armed for battle. Nat. Rev. Immunol. 2014;14:478–94.
Lieberman P, Garvey LH. Mast Cells and Anaphylaxis. Curr. Allergy Asthma Rep. 2016;16:1–7.
Afrin LB. Mast cell activation disease and the modern epidemic of chronic inflammatory disease. Transl. Res. 2016;174:33–59.
Veatch SL, Chiang EN, Sengupta P et al. Quantitative nanoscale analysis of IgE-FcεRI clustering and coupling to early signaling proteins. J Phys Chem B 2012;116:6923–35.
Mukai K, Matsuoka K, Taya C et al. Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells. Immunity 2005;23:191–202.
Weller K, Foitzik K, Paus R et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J 2006;20:2366–8.
He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J. Gastroenterol. 2004;10:309–18.
Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells: What each is teaching us about the others. Am. J. Pathol. 1993;142:965–74.
Arinobu Y, Iwasaki H, Gurish MF, et al. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A 2005;102:18105–10.
Gurish MF, Boyce JA. Mast cells: Ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol 2006;117:1285–91.
Metcalfe DD. Mast cells and mastocytosis. Blood 2008;112:946–56.
Galli SJ. Complexity and redundancy in the pathogenesis of asthma: Reassessing the roles of mast cells and T cells. J. Exp. Med. 1997;186:343–7.
Theoharides TC, Donelan JM, Papadopoulou N et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004;25:563–8.
Grimbaldeston MA, Nakae S, Kalesnikoff J et al. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007;8:1095–104.
Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 2008;8:478–86.
Biggs L, Yu C, Fedoric B et al. Evidence that vitamin D3 promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice. J Exp Med 2010;207:455–63.
Penna G, Adorini L. 1α,25-Dihydroxyvitamin D 3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation . J Immunol 2000;164:2405–11.
Babina M, Krautheim M, Grützkau A et al. Human leukemic (HMC-1) mast cells are responsive to 1α,25-dihydroxyvitamin D3: Selective promotion of ICAM-3 expression and constitutive presence of vitamin D3 receptor. Biochem Biophys Res Commun 2000;273:1104–10.
Toyota N, Sakai H, Takahashi H et al. Inhibitory effect of 1α,25-dihydroxyvitamin D3 on mast cell proliferation and A23187-induced histamine release, also accompanied by a decreased c-kit receptor. Arch Dermatol Res 1996;288:709–15.
Adorini L. Intervention in autoimmunity: The potential of vitamin D receptor agonists. In: Cellular Immunology. Cell Immunol 2005: 115–24.
Staeva-Vieira TP, Freedman LP. 1,25-Dihydroxyvitamin D 3 Inhibits IFN-γ and IL-4 Levels During In Vitro Polarization of Primary Murine CD4 + T Cells . J Immunol 2002;168:1181–9.
O’Kelly J, Hisatake J, Hisatake Y,et al. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002;109:1091–9.
Wittke A, Weaver V, Mahon BD et al. Vitamin D Receptor-Deficient Mice Fail to Develop Experimental Allergic Asthma. J Immunol 2004;173:3432–6.
Baroni E, Biffi M, Benigni F, et al. VDR-dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D 3 . J Leukoc Biol 2007;81:250–62.
Liu ZQ, Li XX, Qiu SQ et al. Vitamin D contributes to mast cell stabilization. Allergy Eur J Allergy Clin Immunol 2017;72:1184–92.
Haşlak F, Özçeker D, Tamay Z Sütçocuğunda Ender Bir Döküntü Nedeni: Kutanöz Mastositoz Vaka Sunumu. Çocuk Derg 2014;14:116–20.
Hussain SH. Pediatric mastocytosis. Curr. Opin. Pediatr. 2020;32:531–8.
Cohen SS, Skovbo S, Vestergaard H et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 2014;166:521–8.
Méni C, Bruneau J, Georgin-Lavialle S et al. Paediatric mastocytosis: A systematic review of 1747 cases. Br. J. Dermatol. 2015;172:642–51.
Matito A, Álvarez-Twose I, Morgado JM et al. Clinical impact of pregnancy in mastocytosis: A study of the Spanish network on mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol 2011;156:104–11.
Bodemer C, Hermine O, Palmérini F et al. Pediatric mastocytosis is a clonal disease associated with D 816 v and other activating c-KIT mutations. J Invest Dermatol 2010;130:804–15.
Matito A, Azaña JM, Torrelo A et al. Cutaneous Mastocytosis in Adults and Children: New Classification and Prognostic Factors. Immunol. Allergy Clin. North Am. 2018;38:351–63.
Hartmann K, Escribano L, Grattan C et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; The American Academy of Allergy, Asthma & Immunology; And the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016;137:35–45.
Brockow K, Ring J. Extensive blistering is a predictor for severe complications in children with mastocytosis. Allergy Eur. J. Allergy Clin. Immunol. 2012;67:1323.
Brockow K, Akin C, Huber M et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003;48:508–16.
Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:519–28.
Kiszewski AE, Alvarez-Mendoza A, Ríos-Barrera VA et al. Mastocytosis in children: Clinicopathological study based on 35 cases. Histol Histopathol 2007;22:535–9.
Ertugrul A, Bostanci I Pediatric cutaneous mastocytosis and c-KIT mutation screening. In: Allergy and Asthma Proceedings. OceanSide Publications Inc. 2019: 123–8.
Alvarez-Twose I, Vañõ-Galván S, Sánchez-Muñoz L et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy Eur J Allergy Clin Immunol 2012;67:813–21.
Brockow K, Jofer C, Behrendt H et al. Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients. Allergy Eur J Allergy Clin Immunol 2008;63:226–32.
Mackey S, Pride HB, Tyler WB. Diffuse cutaneous mastocytosis: Treatment with oral psoralen plus UV-A. Arch Dermatol 1996;132:1429–30.
